Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12...1011121314151617181920...858859»
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Enrollment closed:  A Study of Romosozumab (EVENITY (clinicaltrials.gov) -  Nov 17, 2024   
    P4,  N=100, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  The deleterious effects of CDK4/6 inhibition on renal recovery post-acute kidney injury. (Pubmed Central) -  Nov 17, 2024   
    We found that Palb could reverse the senolytic and antifibrotic effects induced by D?+?Q, which indicates that the profibrotic effect of Palb could be ascribed to its pro-senescent effects. Our results demonstrate that CDK4/6 inhibitors treatment might be deleterious on the chronic sequence of AKI.
  • ||||||||||  Krazati (adagrasib) / BMS, divarasib (RG6330) / Roche, Lumakras (sotorasib) / Amgen
    Review, Journal, Metastases:  An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer. (Pubmed Central) -  Nov 16, 2024   
    KRASG12C inhibitors sotorasib, adagrasib and the newer divarasib, has revolutionized treating patients harboring this mutation. Ongoing studies and future clinical trials will refine our understandings with the ultimate goal of improving survival and quality of life for patients with this challenging disease.
  • ||||||||||  Journal:  Network-Based Drug Repurposing and Genomic Analysis to Unveil Potential Therapeutics for Monkeypox Virus. (Pubmed Central) -  Nov 16, 2024   
    In addition, the pharmacophore-based screening identified a molecule that is comparable to Baricitinib and has the potential to be effective against MPXV. The findings of the study suggest that ZINC22060520 is a promising medication for treating MPXV infection and proposes these medications as potential options for additional experimental and clinical assessment in the battle against MPXV.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Journal:  Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis. (Pubmed Central) -  Nov 16, 2024   
    The findings of the study suggest that ZINC22060520 is a promising medication for treating MPXV infection and proposes these medications as potential options for additional experimental and clinical assessment in the battle against MPXV. Patients with uncontrolled gout experienced an increase in the clinical burden of disease and HCRU in the 2
  • ||||||||||  Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
    Journal:  Inebilizumab for Treatment of IgG4-Related Disease. (Pubmed Central) -  Nov 16, 2024   
    P3
    Inebilizumab reduced the risk of flares of IgG4-related disease and increased the likelihood of flare-free complete remission at 1 year, confirming the role of CD19-targeted B-cell depletion as a potential treatment for IgG4-related disease. (Funded by Amgen; MITIGATE ClinicalTrials.gov number, NCT04540497.).
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Enrollment change:  G-CSF After Chemo-radiation in Patients with Glioblastoma (clinicaltrials.gov) -  Nov 16, 2024   
    P2,  N=40, Not yet recruiting, 
    Further studies are needed to confirm our findings. N=60 --> 40
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
    Journal, Adverse events:  Cyclin-dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database. (Pubmed Central) -  Nov 16, 2024   
    Recent trials have highlighted the cardiotoxicity of ribociclib, a CDK4/6 inhibitor, particularly its association with QT prolongation...For the first time, palbociclib has been identified with positive signals for cardiotoxic events at the preferred terms level, including pulmonary oedema, increased blood pressure, myocardial infarction, and cardiac flutter...Our study also highlights significant drug interactions that increase the probability of specific cardiotoxic outcomes, notably with drugs like sertraline, lansoprazole, capecitabine, and torasemide. These findings highlight the need for personalized treatment plans to mitigate cardiotoxic events and improve patient safety.
  • ||||||||||  Prolia (denosumab) / Amgen
    Clinical, Journal:  Denosumab for osteoporosis in older adults in long-term care: A randomized trial. (Pubmed Central) -  Nov 16, 2024   
    These findings highlight the need for personalized treatment plans to mitigate cardiotoxic events and improve patient safety. Denosumab was a safe and effective therapy for improving BMD in osteoporotic older men and women with multiple comorbidities in LTC.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono
    Journal:  Recurrent late-onset neutropenia following treatment with different B cell-depleting strategies in multiple sclerosis. (Pubmed Central) -  Nov 15, 2024   
    The systematic review findings emphasise the significance of considering non-statin LLTs as viable treatment options for individuals with CVD or high cardiovascular risk who cannot tolerate or achieve optimal lipid control with statin therapy alone. This case highlights the significance of symptomatic late-onset blood count changes under both ocrelizumab and ofatumumab and emphasizes the importance of continuous monitoring of the differential blood count under B cell-depleting treatment.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases:  Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer. (Pubmed Central) -  Nov 15, 2024   
    This study confirms first-line CDK 4/6i effectiveness, with abemaciclib and ribociclib showing prolonged PFS vs. palbociclib. This study could not confirm a ranking of the three CDK 4/6i.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Enbrel (etanercept) / Pfizer, Amgen
    Journal:  A novel functional IKBKE variant activating NFAT in a patient with polyarthritis and a remittent fever. (Pubmed Central) -  Nov 15, 2024   
    A novel functional heterozygous variant in IKBKE is described in a patient with a remittent fever and arthritis. The data suggest that IKBKE is an important negative regulator of inflammation, particularly in T cells, and this IKBKE variant might be the underlying cause of a novel autoinflammatory pathology.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Retrospective data, Review, Journal:  Teprotumumab's Impact on Proptosis in Long-duration Thyroid Eye Disease: A Systematic Review and Meta-analysis. (Pubmed Central) -  Nov 15, 2024   
    Further research is essential to understand teprotumumab's long-term efficacy and comparative advantages over surgical options. These findings have significant implications for treating persistent proptosis in patients with long-duration TED, potentially offering a non-surgical alternative where options were previously limited.
  • ||||||||||  Tavneos (avacopan) / Amgen
    Review, Journal:  Avacopan for antineutrophil cytoplasmic antibody-associated vasculitis. (Pubmed Central) -  Nov 15, 2024   
    These findings have significant implications for treating persistent proptosis in patients with long-duration TED, potentially offering a non-surgical alternative where options were previously limited. No abstract available
  • ||||||||||  Prolia (denosumab) / Amgen
    Enrollment closed, Enrollment change:  FITMI - First In Treating Male Infertility (clinicaltrials.gov) -  Nov 15, 2024   
    P2,  N=180, Active, not recruiting, 
    Trial primary completion date: Sep 2024 --> Jun 2025 Recruiting --> Active, not recruiting | N=282 --> 180
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    Trial completion:  EVACS II: Evolocumab in Patients With Acute MI (clinicaltrials.gov) -  Nov 15, 2024   
    P2,  N=100, Completed, 
    Recruiting --> Active, not recruiting | N=282 --> 180 Active, not recruiting --> Completed
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    Trial completion:  EVACS: Evolocumab in Acute Coronary Syndrome (clinicaltrials.gov) -  Nov 15, 2024   
    P2,  N=60, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Ingavirin (imidazolyl ethanamide pentandioic acid) / Myelo Therap, Valenta Pharm, Neulasta (pegfilgrastim) / Roche
    Preclinical, Journal:  IEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents. (Pubmed Central) -  Nov 14, 2024   
    In children with HeFH, evolocumab plus statin treatment up to 104 weeks led to regression in carotid arterial wall thickening. IEPA (imidazolyl ethanamide pentandioic acid) is an orally bioavailable small molecule pseudopeptide with myeloprotective properties, a good clinical safety profile, and stable chemical characteristics facilitating stockpiling...IEPA treatment is compatible with Neulasta
  • ||||||||||  rocatinlimab (KHK4083) / Amgen
    Clinical, P2b data, Journal, Patient reported outcomes:  Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase (Pubmed Central) -  Nov 14, 2024   
    P2
    IEPA (imidazolyl ethanamide pentandioic acid) is an orally bioavailable small molecule pseudopeptide with myeloprotective properties, a good clinical safety profile, and stable chemical characteristics facilitating stockpiling...IEPA treatment is compatible with Neulasta This analysis demonstrates the importance of characterizing the burden of moderate-to-severe AD from the patient's perspective, alongside clinical disease measures, to develop a fuller picture of treatment benefit.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Journal, Stroma:  Stromal Reprogramming Optimizes KRAS-Specific Chemotherapy Inducing Antitumor Immunity in Pancreatic Cancer. (Pubmed Central) -  Nov 14, 2024   
    The molecular mechanisms elucidated that the stroma intervention and KRAS signal pathway regulation reshaped the immunosuppression of PDAC and optimized cytotoxic T-cell-mediated antitumor immunity with sustained antitumor memory. Overall, our study provides a practical strategy with clinical translational promise for immunologically cold tumor PDAC treatment.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Trial completion date:  AMG 510 Ethnic Sensitivity Study (CodeBreaK 105). (clinicaltrials.gov) -  Nov 14, 2024   
    P1,  N=12, Active, not recruiting, 
    No abstract available Trial completion date: Dec 2024 --> Jun 2025